BUZZ-SpringWorks Therapeutics rises as canceled earnings call raises buyout hopes

Shares of drugmaker SpringWorks Therapeutics SWTX.O rise 10.12% to $61.37 premarket

Co says it will not host a conference call to discuss its quarterly earnings, which Evercore ISI analysts say confirms that its negotiations with Germany's Merck KGaA MRCG.DE for a potential buyout "are still very much alive"

Reuters reported on February 10 that Germany's Merck KGaA MRCG.DE was in advanced talks to acquire the company; Merck subsequently confirmed the talks

Separately, SpringWorks posts Q4 revenue of $61.5 mln, versus analysts' est of $59.1 mln, as per data compiled by LSEG

"This morning's 4Q print is in-line (recall January pre-announcement) and irrelevant," says Evercore ISI

Stock has risen 3.2% since the Reuters report and 13.5% in the past 12 months